Skip to main content

WELLS FARGO & COMPANY/MN

Position in ACAD — Acadia Pharmaceuticals Inc

CIK 72971 SAN FRANCISCO, CA

Position in ACAD

as of Mar 31, 2026 · filed May 11, 2026
Position Value
$2,638,365
-$2,949,045 QoQ
Shares Held
118,525
-43.3% QoQ
Ownership
0.069%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 95.49040286859312.ToString("F0")% Shared 0.ToString("F0")% None 4.509597131406876.ToString("F0")%

Common Shares in ACAD Over Time

Shares Held

Position Value (USD)

Derivatives in ACAD

reported options exposure · as of Mar 31, 2021
CallValue
$1,290,000
CallShares
50,000
PutValue
$129,000
PutShares
5,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

WELLS FARGO & COMPANY/MN holds $1,292,861,286 across 390 Biotechnology names. ACAD ranks #55 (0.2% of the industry book) .

# Ticker Company Shares Value (USD) Open

All Filings in ACAD

Export CSV
27 filing rows on record
Report Date Value (USD) Shares
2026-03-31 $2,638,365 118,525
2025-12-31 $5,587,410 209,188
2025-09-30 $3,218,135 150,803
2025-06-30 $2,991,628 138,694
2025-03-31 $3,317,762 199,745
2024-12-31 $3,713,103 202,349
2024-09-30 $2,889,931 187,902
2024-06-30 $3,017,900 185,717
2024-03-31 $1,884,499 101,920
2023-12-31 $2,761,508 88,199
2023-09-30 $3,003,458 144,120
2023-06-30 $4,477,617 186,957
2023-03-31 $3,373,050 179,227
2022-12-31 $1,608,508 101,037
2022-09-30 $1,688,366 103,201
2022-06-30 $1,462,341 103,786
2022-03-31 $4,009,449 165,543
2021-12-31 $4,772,048 204,458
2021-09-30 $3,258,663 196,187
2021-06-30 $3,863,154 158,391
2021-03-31 $129,000 5,000
2021-03-31 $3,993,916 154,803
2021-03-31 $1,290,000 50,000
2020-12-31 $9,464,929 177,047
2020-09-30 $8,313,029 201,528
2020-06-30 $10,556,811 217,801
2020-03-31 $9,720,076 230,061